viimane versioon :
19/11/2024
uurimisrühmad - Universidad Complutense de Madrid,Facultad de Farmacia   pdf  
Hispaania
ülikool
Universidad Complutense de Madrid,Facultad de Farmacia
Madrid
Viited   Viited   (12)  
1
Stability of daptomycin reconstituted vials and infusion solutions.
Ferrandez J, Sanchez R, Diaz D, Diaz M, Estevan M, Garcia T. (sanchez@salud.madrid.org)
EJHP - 2018 - ; 25: 107-110.
2
Stability of carboplatin infusion solutions used in desensitization protocol.
Vazquez-Sanchez R, Sanchez-Rubio-Ferrandez J, Cordoba-Diaz D, Cordoba-Diaz M, Molina-Garcia T. (rovazsan@hotmail.com)
J Oncol Pharm Practice - 2018 - 25,5:1076?1081
3
Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine.
Negro S, Martin A, Azuara L, Sanchez Y, Barcia E. ()
J Palliat Med - 2010 - ; 13, 3: 273-277.
4
Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability.
Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S. (ebarcia@farm.ucm.es)
Support Care Cancer - 2007 - ; 15: 57-62.
5
Compatibility and stability of tramadol and dexamethasone in solution and its use in terminally ill patients.
Negro S, Salama A, S?nchez Y, AzuaraM.L, Barcia B. (soneal@farm.ucm.es)
J Clin Pharm Ther - 2007 - ; 32: 441-444.
6
Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients.
Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. (soneal@farm.ucm.es )
Int J Pharm - 2006 - ; 307: 278-284.
7
Compatibility and stability of furosemide and dexamethasone combined in infusion solutions.
Negro S, Rendon AL, Azuara ML, S?nchez Y, Fern?ndez-Carballido A, Barcia E. ( soneal@farm.ucm.es)
Arzneimittel Forschung - 2006 - ; 56, 10: 714-720.
8
Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide.
Barcia E, Reyes R, Azuara L, Sànchez Y, Negro S. ()
Support Care Cancer - 2005 - ; 13, 4: 239-245.
9
Stability of tramadol and haloperidol for continuous infusion at home.
Negro S, Martin A, Azuara ML, Sanchez Y, Barcia E. ()
J Pain Symptom Manage - 2005 - ; 30: 192-199.
10
Stability study of an aqueous formulation of captopril at 1 mg/ml.
Escribano Garcia MJ, Torrado Duran S, Torrado Duran JJ. (torrado2@farm.ucm.es)
Farm Hosp - 2005 - ; 29: 30-36.
11
Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care.
Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S. ()
Support Care Cancer - 2003 - ; 11, 2: 107-113.
12
Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care.
Azuara ML, Sanchez Y, Reyes R, Barcia E. (soneal @eucmax.sim.ucm.es)
Support Care Cancer - 2001 -

ingredientide nimekiri   molekulid uuritud   (11)  
Antihüpertensiivne ravim suukaudne lahus Captopril
vähiravimite Süsteravim Carboplatin
antibiootikum Süsteravim Daptomycin
Põletikuvastane ravim Süsteravim Dexamethasone sodium phosphate
diureetikum Süsteravim Furosemide
neuroleptikum Süsteravim Haloperidol lactate
antiemeetikum Süsteravim Metoclopramide hydrochloride
Anksiolüütiline ravim Süsteravim Midazolam hydrochloride
analgeetikum Süsteravim Morphine hydrochloride
Antimuskarinergiline ravim Süsteravim Scopolamine N-butyl bromide
analgeetikum Süsteravim Tramadol hydrochloride

  Mentions Légales